Corstasis Therapeutics is a biopharmaceutical company focused on creating better outpatient treatments for patients with cardiovascular and kidney diseases. The company's main product is ENBUMYST™ (bumetanide nasal spray), which is the first intranasal loop diuretic to receive FDA approval. Corstasis is also developing a pipeline of subcutaneous diuretic products. The company aims to improve patient care, reduce hospital stays, and lower healthcare costs by developing practical new treatments for edema associated with conditions like congestive heart failure, liver disease, and kidney disease.